樂
樂觀
樂觀 · 25%AZN
$82.29
情境價格
$171.490
-1.080 (-0.63%)收盤時
Loading chart…
- 最高
- 171.750
- 開盤
- 171.280
- 成交量加權均價
- 170.92
- 成交量
- 3.69M
- 市值
- 242.40B
- 最低
- 169.510
- 成交金額
- 630.92M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 13.01
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
AI 分析 of AstraZeneca PLC (AZN)
買進AstraZeneca is a good buy right now, trading at $165.41 with a forward P/E of 14.62, suggesting it is undervalued compared to its growth potential. The RSI is at 65.38, indicating bullish momentum, while the recent strategic collaboration with insitro could drive future revenue growth. The main risk is the year-to-date decline of 9.45%, reflecting market concerns that could impact short-term performance.
分析師評級（5）
上檔空間 +24.58%
買進
4 買進
1 持有
0 賣出
目前: 171.49
最低
157.61
平均
213.64
最高
252.18
Citi
買進
—
2026-10-06
Citi
2026-10-06
目標價
—
買進
Berenberg
買進
—
2026-09-15
Berenberg
2026-09-15
目標價
—
買進
Deutsche Bank
持有
—
2026-09-15
Deutsche Bank
2026-09-15
目標價
—
持有
HSBC
持有
—
2026-09-10
HSBC
2026-09-10
目標價
—
持有
RBC Capital
優於大盤
—
2026-09-08
RBC Capital
2026-09-08
目標價
—
優於大盤
估值指標
AstraZeneca PLC（AZN）目前預期本益比為 14.62，5 年平均預期本益比為 16.35。
Alphio AI 對 AZN 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
持有 AZN 的大戶
事件時間軸
資訊
2.010-21FoolAlnylam Pharmaceuticals Shares Plunge 40% Amidst Profitability Concerns
2.010-19stocktwitsSellas Life Sciences Faces Pressure on Regal Trial Results Ahead of ASH
7.510-17stocktwitsGilead Partners with Vir to Develop Cancer Drugs
7.510-15stocktwitsAstraZeneca Enters Strategic Collaboration with insitro for Drug Discovery
8.510-12stocktwitsSellas Life Sciences Shares Rise 3% Amid ASH Meeting Speculation
AZN 常見問題 —— 由 Alphio AI 解答
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
AstraZeneca is a good buy right now, trading at $165.41 with a forward P/E of 14.62, suggesting it is undervalued compared to its growth potential. The RSI is at 65.38, indicating bullish momentum, while the recent strategic collaboration with insitro could drive future revenue growth. The main risk is the year-to-date decline of 9.45%, reflecting market concerns that could impact short-term performance.
5 analysts cover AZN: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 213.64.
社群
更多 ↗
AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes Partnership aims to advance solutions to improve care pathways, clinical trial matching, safety monitoring, and guideline-directed care AstraZeneca and Oracle Health and Life Sciences today announced a unique collaboration to leverage AstraZeneca's scientific, clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure, and AI-enabled clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to accelerate clinical trial optimisation and help more patients receive the right care sooner. $AZN $ORCL
展開
$SMMT just landed a major combo opportunity for ivonescimab — and Datroway is the key. Summit is teaming with AstraZeneca ($AZN) and Daiichi Sankyo to evaluate ivonescimab with Datroway, a TROP2-targeted ADC jointly developed and commercialized by Daiichi and AstraZeneca. The initial focus is a Phase III study in first-line TNBC, while the collaboration plans to evaluate the combo across multiple solid tumors, including breast and lung cancers. Latest SMMT news here
展開
$SMMT $AZN Citi raised its price target on Summit Therapeutics (SMMT) to $43 from $40 and keeps a Buy rating on the shares after the company announced a $2B investment from AstraZeneca (AZN). AstraZeneca's $2B investment in convertible preferred shares is equivalent to $18.36 per common share, representing a 19% premium to Summit's latest closing price, the analyst tells investors in a research note. Citi views the deal as a "de-risking event" that removes Summit's financing overhang.
展開
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。